158 related articles for article (PubMed ID: 24923488)
21. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
Feng H; Li B; Li Z; Wei Q; Ren L
BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
[TBL] [Abstract][Full Text] [Related]
22. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease.
Beale G; Chattopadhyay D; Gray J; Stewart S; Hudson M; Day C; Trerotoli P; Giannelli G; Manas D; Reeves H
BMC Cancer; 2008 Jul; 8():200. PubMed ID: 18638391
[TBL] [Abstract][Full Text] [Related]
23. Development and potential application of a simultaneous multiplex assay of Golgi protein 73 and alpha-fetoprotein for hepatocellular carcinoma diagnosis.
Xiao J; Long F; Peng T; Hu LB; Cai H; Chen R; Chen WL
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3302-3310. PubMed ID: 31081083
[TBL] [Abstract][Full Text] [Related]
24. Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System.
Tayob N; Richardson P; White DL; Yu X; Davila JA; Kanwal F; Feng Z; El-Serag HB
BMC Med Res Methodol; 2018 Jan; 18(1):1. PubMed ID: 29301497
[TBL] [Abstract][Full Text] [Related]
25. The Role of Dermcidin in the Diagnosis and Staging of Hepatocellular Carcinoma.
Qiu F; Qiu F; Liu L; Liu J; Xu J; Huang X
Genet Test Mol Biomarkers; 2018 Apr; 22(4):218-223. PubMed ID: 29641283
[TBL] [Abstract][Full Text] [Related]
26. Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma.
Vongsuvanh R; van der Poorten D; Iseli T; Strasser SI; McCaughan GW; George J
PLoS One; 2016; 11(5):e0155800. PubMed ID: 27219517
[TBL] [Abstract][Full Text] [Related]
27. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
[TBL] [Abstract][Full Text] [Related]
28. Factors that affect accuracy of α-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis.
Gopal P; Yopp AC; Waljee AK; Chiang J; Nehra M; Kandunoori P; Singal AG
Clin Gastroenterol Hepatol; 2014 May; 12(5):870-7. PubMed ID: 24095974
[TBL] [Abstract][Full Text] [Related]
29. A prospective study of blood alpha-fetoprotein messenger RNA as a predictor of hepatocellular carcinoma in patients with cirrhosis.
Iavarone M; Lampertico P; Ronchi G; Del Ninno E; Zanella A; Colombo M
J Viral Hepat; 2003 Nov; 10(6):423-6. PubMed ID: 14633174
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of squamous cell carcinoma antigen-immunoglobulin M complex (SCCA-IGM) and alpha-L-fucosidase (AFU) as novel diagnostic biomarkers for hepatocellular carcinoma.
Mossad NA; Mahmoud EH; Osman EA; Mahmoud SH; Shousha HI
Tumour Biol; 2014 Nov; 35(11):11559-64. PubMed ID: 25129443
[TBL] [Abstract][Full Text] [Related]
31. A Novel Blood-Based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma.
Chalasani NP; Ramasubramanian TS; Bhattacharya A; Olson MC; Edwards V DK; Roberts LR; Kisiel JB; Reddy KR; Lidgard GP; Johnson SC; Bruinsma JJ
Clin Gastroenterol Hepatol; 2021 Dec; 19(12):2597-2605.e4. PubMed ID: 32889146
[TBL] [Abstract][Full Text] [Related]
32. Serum thioredoxin is a diagnostic marker for hepatocellular carcinoma.
Li J; Cheng ZJ; Liu Y; Yan ZL; Wang K; Wu D; Wan XY; Xia Y; Lau WY; Wu MC; Shen F
Oncotarget; 2015 Apr; 6(11):9551-63. PubMed ID: 25871387
[TBL] [Abstract][Full Text] [Related]
33. Clinical evaluation of urinary transforming growth factor-beta1 and serum alpha-fetoprotein as tumour markers of hepatocellular carcinoma.
Tsai JF; Jeng JE; Chuang LY; Yang ML; Ho MS; Chang WY; Hsieh MY; Lin ZY; Tsai JH
Br J Cancer; 1997; 75(10):1460-6. PubMed ID: 9166938
[TBL] [Abstract][Full Text] [Related]
34. Early detection of hepatocellular carcinoma co-occurring with hepatitis C virus infection: A mathematical model.
Zekri AR; Youssef AS; Bakr YM; Gabr RM; Ahmed OS; Elberry MH; Mayla AM; Abouelhoda M; Bahnassy AA
World J Gastroenterol; 2016 Apr; 22(16):4168-82. PubMed ID: 27122667
[TBL] [Abstract][Full Text] [Related]
35. Urinary transforming growth factor-beta 1 in relation to serum alpha-fetoprotein in hepatocellular carcinoma.
Tsai JF; Jeng JE; Chuang LY; Chang WY; Hsieh MY; Lin ZY; Tsai JH
Scand J Gastroenterol; 1997 Mar; 32(3):254-60. PubMed ID: 9085463
[TBL] [Abstract][Full Text] [Related]
36. Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker.
Chen L; Ho DW; Lee NP; Sun S; Lam B; Wong KF; Yi X; Lau GK; Ng EW; Poon TC; Lai PB; Cai Z; Peng J; Leng X; Poon RT; Luk JM
Ann Surg Oncol; 2010 Sep; 17(9):2518-25. PubMed ID: 20354800
[TBL] [Abstract][Full Text] [Related]
37. Serum metabolites may be useful markers to assess vascular invasion and identify normal alpha-fetoprotein in hepatocellular carcinoma undergoing liver resection: a pilot study.
Lee CW; Yu MC; Lin G; Chiu JC; Chiang MH; Sung CM; Hsieh YC; Kuo T; Lin CY; Tsai HI
World J Surg Oncol; 2020 Jun; 18(1):121. PubMed ID: 32493393
[TBL] [Abstract][Full Text] [Related]
38. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
[TBL] [Abstract][Full Text] [Related]
39.
Lee HA; Lee YR; Lee YS; Jung YK; Kim JH; An H; Yim HJ; Jeen YT; Yeon JE; Byun KS; Seo YS
World J Gastroenterol; 2021 Jul; 27(28):4687-4696. PubMed ID: 34366629
[TBL] [Abstract][Full Text] [Related]
40. Longitudinal Assessment of Three Serum Biomarkers to Detect Very Early-Stage Hepatocellular Carcinoma.
Choi J; Kim GA; Han S; Lee W; Chun S; Lim YS
Hepatology; 2019 May; 69(5):1983-1994. PubMed ID: 30153338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
